• Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

    Source: Nasdaq GlobeNewswire / 03 Aug 2023 08:00:00   America/New_York

    Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

    (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 10, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide a business and portfolio update.

    Audio Webcast
    The call will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.

    Conference Call Details:
    Domestic (toll-free): 877-405-1239
    International (toll): +1 201-389-0851

    ##

    About Immunocore

    Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

    CONTACT: 

    Immunocore
    Sébastien Desprez, Head of Communications
    T: +44 (0) 7458030732
    E: sebastien.desprez@immunocore.com
    Follow on Twitter: @Immunocore

    Investor Relations  
    Clayton Robertson, Head of Investor Relations
    T: +1 215-384-4781
    E: ir@immunocore.com


    Primary Logo

Share on,